Shares of Capricor Therapeutics (CAPR) fell 8% on Friday, extending this week's selloff, after key regulatory setbacks for its lead experimental treatment for Duchenne muscular dystrophy, Deramiocel.The stock has closed lower for five consecutive days, erasing nearly 80% from the company’s market c…
Capricor Therapeutics, Inc. (CAPR), LKQ Corp. (LKQ), and Paramount Skydance Corp. (PSKY) stocks touched 52-week lows on Thursday as regulatory concerns, operational disruptions, and legal uncertainty each weighed heavily on investors’ sentiment.Capricor stock plunged 36% and is on track for its wor…
Capricor Therapeutics said an FDA advisory committee voted that available evidence did not support Deramiocel's effectiveness for DMD cardiomyopathy (3 for, 9 against, 0 abstain).Key Highlights:Original SEC Filing: CAPRICOR THERAPEUTICS, INC. [ CAPR ] - 8-K - Jul. 30, 2026This is an AI-powered summ…
Capricor investors lost 60% to 70% after FDA briefing documents raised significant concerns regarding Deramiocel, following earlier Company statements that the FDA had not identified material review issues.NEW YORK, July 30, 2026 /PRNewswire/ -- FDA staff briefing documents released on July 27, 202…
Shares of Capricor Therapeutics (CAPR) slumped nearly 58% in pre-market trading on Thursday, with Wall Street sharply cutting its expectations following a U.S. Food and Drug Administration (FDA) advisory panel’s 9-3 vote against Deramiocel, raising doubts about the Duchenne muscular dystrophy thera…
Shares of Capricor Therapeutics, Inc. (CAPR) are on track for a record weekly selloff after an Food and Drug Administration (FDA) advisory panel voted 9-3 against Deramiocel, even as retail investors continue to bet that the Duchenne muscular dystrophy (DMD) therapy could still secure some form of…
LOS ANGELES, July 29, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR) investors concerning the Company'…
Capricor Therapeutics (CAPR) has received a significant boost after The Lancet published results from its much-discussed Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy (DMD).The publication comes ahead of a crucial U.S. Food and Drug Administration (FDA) advisory committee meeti…
Shares of Capricor Therapeutics (CAPR) are staring at their worst month in nine years after a 65% plunge on FDA doubts over Deramiocel, its Duchenne muscular dystrophy (DMD) cell therapy. The rout has given former pharma executive Martin Shkreli fresh ammunition, even as retail traders turn more bu…
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics NASDAQ:CAPR, a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead of the Company's upcoming FDA Advisory Committee meeting, at which an independent a…
Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat cardiomyopathy in patients with Duchenne muscul…
Shares of Capricor Therapeutics (CAPR) advanced this week, positioning the biotech for its first weekly gain in five weeks after a 33% decline over the past month, as investors await an FDA committee meeting on the company’s application, which investors deem to be a binary event.On Thursday, the st…
